Gap seen in cardiovascular, psychiatry, and cancer trial participation versus national prevalence disease data<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 23, 2022 (HealthDay News) — Sex-based gaps still persist in women’s participation in drug and device clinical trials, according to a study published in the April issue of Contemporary Clinical Trials<\/em>.<\/p>\n Alexandra Z. Sosinsky, from Brigham and Women’s Hospital in Boston, and colleagues analyzed data from ClinicalTrials.gov on U.S.-based, pharmaceutical industry or government-funded phase 1 to 3 clinical trials (2016 to 2019) to compare proportions of women enrolled in trials for adult cardiovascular, psychiatric, and cancer drugs and devices.<\/p>\n The researchers found that across 1,433 trials (302,664 participants), on average, 41.2 percent of participants were women. Women were consistently underrepresented versus their proportion of the disease population (cardiovascular disease: 41.9 percent female participants versus 49 percent female population with cardiovascular disease; psychiatry: 42 percent clinical trial participation versus 60 percent of patient population; cancer: 41 percent clinical trial participation versus 51 percent of patient population).<\/p>\n “The rise of female participants in clinical trials is certainly promising, but our work is not complete. We simply cannot rest,” a coauthor said in a statement. “To ensure that our patients are properly cared for and drugs as well as devices are truly safe and effective, we need to continue monitoring women s representation in clinical trials by disease area and, importantly, we need to develop interventions and approaches ensuring the inclusion of a diverse group of women in clinical research.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n